Ethinyl Estradiol

Bosentan decreases ethinyl estradiol exposure by average of 31%, with decreases up to 66% in individual subjects, reducing hormonal contraceptive effectiveness.

Colesevelam may decrease ethinyl estradiol exposure when coadministered with oral contraceptives. In vivo studies demonstrated decreased exposure. Administer 4 hours prior to colesevelam.

Estrogen-containing oral contraceptives with 30 mcg ethinylestradiol decrease lamotrigine levels approximately 50%.

PYRUKYND induces CYP3A, decreasing systemic concentrations of this hormonal contraceptive. Monitor for loss of contraceptive efficacy or use non-hormonal alternatives.

Levels may be increased when co-administered with atorvastatin.

Effectiveness of steroidal contraceptives may be reduced when used with armodafinil. Alternative or concomitant methods of contraception are recommended during treatment and for one month after discontinuation.

Oral contraceptive component; atorvastatin may increase ethinyl estradiol values.

Avapritinib may increase ethinyl estradiol exposure, leading to increased risk of ethinyl estradiol-associated adverse reactions. Use formulations with ≤20 mcg ethinyl estradiol.

Component of oral contraceptives; can cause adverse events like diarrhea, nausea, abdominal pain when coadministered. Use with caution.

Colesevelam may decrease exposure of oral contraceptives containing ethinyl estradiol and norethindrone.

Elagolix increases ethinyl estradiol plasma concentrations. Use effective non-hormonal contraception during treatment and for 28 days after discontinuation.

Eslicarbazepine acetate is associated with lower plasma levels of ethinylestradiol, potentially decreasing hormonal contraceptive effectiveness. Additional or alternative non-hormonal birth control is recommended.

Ferric maltol may decrease bioavailability of ethinyl estradiol. Separate administration by at least 4 hours and monitor clinical response.

Fluconazole 200 mg increased ethinyl estradiol AUC by 38% and fluconazole 300 mg increased it by 24%. Fluconazole 50 mg showed no significant effect.

Temsavir increases ethinyl estradiol concentrations; daily dose should not exceed 30 mcg. Caution advised in patients with thromboembolic risk factors.

Estrogen-containing oral contraceptives decrease lamotrigine concentrations approximately 50%. Lamotrigine may decrease levonorgestrel component by 19%.

Teriflunomide may increase systemic exposure of ethinylestradiol. Consideration should be given to type or dose of oral contraceptives used with leflunomide.

Teriflunomide may increase systemic exposure of ethinylestradiol. Consider contraceptive type or dose adjustment.

Effectiveness of steroidal contraceptives may be reduced when used with modafinil. Alternative or concomitant contraception methods recommended during treatment and for one month after discontinuation.

Nevirapine decreases ethinyl estradiol plasma levels. Oral contraceptives should not be used as sole contraception method; alternative or additional contraception recommended.

Hormonal contraceptive effectiveness may be reduced during and for 21 days after WAKIX discontinuation. Use alternative non-hormonal contraceptive.

Oral contraceptive component that may increase roflumilast systemic exposure and result in increased side effects when co-administered.

Estrogen that reduces oral clearance of ropinirole by 36%; starting or stopping may require dose adjustment of ropinirole.

Teriflunomide may increase systemic exposure of ethinylestradiol. Consideration should be given to the type or dose of contraceptives used.

Ethinyl estradiol is a hormonal contraceptive component; unclear if concomitant use with thalidomide increases thromboembolism risk.

Topiramate decreases ethinyl estradiol exposure by 18-30% depending on dose, reducing contraceptive efficacy and increasing breakthrough bleeding.

Component of oral contraceptives; CYP2C19 inhibition may increase voriconazole levels. Monitor for adverse reactions and toxicity.

Component of combination oral contraceptives. Darifenacin had no effect on pharmacokinetics when combined.

Clinical trial showed no clinically relevant changes in pharmacokinetics or hormone levels at recommended isotretinoin dosages.

Concomitant use of tazarotene did not affect the pharmacokinetics of ethinyl estradiol in a trial of 27 healthy female subjects receiving oral contraceptive combination.

Topical application of trifarotene is not expected to affect circulating concentrations of oral hormonal contraceptives containing ethinyl estradiol.

Zafirlukast has no significant effect on ethinyl estradiol plasma concentrations or contraceptive efficacy.